---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-021721"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:53:17.761119+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Abeona Q3 net loss narrows to $5.2M; ZEVASKYN first treatment delayed to Q4 2025

## Summary
- Net loss of $5.2M ($0.10/sh) vs $30.3M ($0.63/sh) in Q3 2024; R&D expense fell to $4.2M, SG&A rose to $19.3M on commercial launch.
- Cash $207.5M at Sep 30, expected to fund operations over two years without ZEVASKYN revenue.
- First ZEVASKYN patient treatment shifted to Q4 2025 after sterility assay false positive; biopsy collection resumed Nov 2025.
- Patient demand growing: 30 eligible patients identified at two QTCs; 12 product order forms received; three centers activated.
- Major commercial payers covering ~60% of RDEB patients; CMS J-code effective Jan 1, 2026; ABO-503 accepted into FDA RDEA program.

## SEC filing metadata
- accession: 0001493152-25-021721
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315225021721/0001493152-25-021721-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315225021721/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-021721
- JSON: https://secwatch.observer/filing/0001493152-25-021721.json
- Plain text: https://secwatch.observer/filing/0001493152-25-021721.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.